Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 146

recruiting
3 982
countries
28
conditions
2 106

2 730 trials match your criteria

Crohn's disease

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Ciprofloxacin

Rhinitis allergic

Not recruiting

Study of Lebrikizumab and Mometasone Furoate for Adults with Perennial Allergic Rhinitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate

Study on the Effects of Itepekimab in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab

Study of Bemcentinib with Pembrolizumab, Carboplatin, and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with STK11 Mutation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib

Carcinoid syndrome

Not recruiting

Study on the Safety and Effects of Paltusotine and Octreotide Acetate for Patients with Carcinoid Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide Acetate

Study of Lu AG22515 for Adults with Moderate-to-Severe Thyroid Eye Disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Human (scFv)2-FAB fusion protein against CD40L

Osteosarcoma metastatic+3

Not recruiting

Study on the Effectiveness and Safety of Regorafenib for Patients with Resistant Primary Bone Tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Regorafenib

Pemphigoid

Not recruiting

Study of dupilumab effectiveness compared to placebo in adults with bullous pemphigoid

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab

Neoplasm malignant

Not recruiting

Study on the Safety of Avelumab, Lorlatinib, and Axitinib for Cancer Patients Continuing from Previous Trials

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Avelumab

Malignant melanoma

Not recruiting

Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.